Akili, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Matthew Franklin
- Full Time Employees
- 68
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 125 Broad Street Boston MA United States of America 02110
- IPO Date
- Jun 30, 2021
- CIK
- 0001850266
- Website
- akiliinteractive.com
- Similar Companies
- Business
- Akili, Inc. is a digital medicine company focused on developing sophisticated digital therapeutics for cognitive impairments. Its flagship product, EndeavorRx, is an innovative video game authorized by the FDA as a prescription treatment to improve attention function in children aged 8 to 17 with ADHD. The company also offers EndeavorOTC, an over-the-counter digital therapeutic for adults with ADHD, utilizing the same core technology. Based in Boston, Massachusetts, Akili has shifted its strategy toward a consumer-led, non-prescription business model, and as of July 2024, operates as a subsidiary of Virtual Therapeutics.
Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game
AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, SGE on Behalf of Shareholders
AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. – AKLI
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI
AKLI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akili, Inc. Is Fair to Shareholders
Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company
Akili Reports First Quarter 2024 Financial Results and Provides Business Update
Why Is Akili (AKLI) Stock Up 68% Today?
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Should You Sell Your Penny Stocks? 3 Tips for When to Sell
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan
Why Is Akili (AKLI) Stock Up 110% Today?
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan